Tesamorelin Confirmed Effective for Long-Term HIV-Associated Lipodystrophy Treatment

Many patients on combination antiretroviral therapy (ART) for HIV develop lipodystrophy, a condition characterized by excess visceral fat accumulation (fat around internal organs), loss of fat in limbs, and metabolic issues like dyslipidemia (abnormal lipid levels) and insulin resistance. Previous research, specifically a Phase 3 trial, showed that TH9507 (Tesamorelin), a growth hormone-releasing factor (GHRF) analog, could reduce this problematic abdominal fat. This extension study was designed to confirm these initial observations and assess the long-term safety and efficacy of TH9507.

The extension study successfully confirmed the positive findings from the initial Phase 3 trial regarding TH9507's impact on HIV-associated lipodystrophy. It demonstrated that continued daily administration of 2 mg TH9507 (Tesamorelin) sustained significant decreases in visceral adipose tissue (VAT) and trunk fat in HIV-infected patients with excess abdominal fat. While specific quantitative data for this extension phase are not detailed in the abstract, the study's aim to 'confirm the observations' implies a consistent effect with the initial trial, which showed beneficial changes over 26 weeks. This sustained reduction in VAT is crucial for mitigating associated metabolic complications. > The extension study successfully confirmed the sustained efficacy of TH9507 in reducing problematic visceral adipose tissue in patients with HIV-associated lipodystrophy, reinforcing its long-term therapeutic potential.